SCHEMBL810353

SCHEMBL810353

Cc1ccc2c(Nc3cc(-c4nc5ccc(Br)cc5[nH]4)ccc3Oc3ccc(OCc4ccccc4)cc3)ncnc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 5/20 0.42
▸ MET P08581 4/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ PIM1 P11309 1/20 0.41
▸ AKT2 P31751 1/20 0.41
▸ ERBB2 P04626 3/20 0.40
▸ EGFR P00533 2/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ PTGES O14684 1/20 0.40
▸ ALOX5 P09917 1/20 0.40
▸ LTC4S Q16873 1/20 0.40
▸ MEN1 O00255 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SCD O00767 1/20 0.38
▸ MMP2 P08253 1/20 0.38
▸ MMP9 P14780 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810595 0.91 MET (0.41) KDRMETCHEK2ERBB2EGFR
SCHEMBL810390 0.90 PIM1 (0.44) KDRMETCHEK2PIM1AKT2
SCHEMBL811239 0.80 MET (0.40) KDRMETCHEK2PIM1AKT2
SCHEMBL810979 0.79 MMP2 (0.45) KDRMETCHEK2MEN1MAPT
SCHEMBL810440 0.77 CHEK2 (0.56) CHEK2PDE4APDE4BPDE4CPDE4D
SCHEMBL810680 0.77 EGFR (0.45) KDRCHEK2PIM1AKT2ERBB2
SCHEMBL810607 0.74 PIM1 (0.59) KDRCHEK2PIM1AKT2ERBB2
SCHEMBL810467 0.73 MAPT (0.52) CHEK2PDE4APDE4BPDE4CPDE4D
SCHEMBL810650 0.69 EGFR (0.47) PIM1AKT2ERBB2EGFRMEN1
SCHEMBL1455253 0.68 AURKA (0.49) KDRERBB2EGFRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 — — EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 — — EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 — — US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 — — EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 — — US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 KDR 3293/4885MET 1405/4885CHEK2 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback